%0 Journal Article
%A Garcia, Santos D.
%A de Deus Fonticoba, Teresa
%A Cores, Carlos
%A Munoz, Guillermo
%A Paz Gonzalez, Jose M.
%A Martinez Miro, Cristina
%A Suarez, Ester
%A Jesus, Silvia
%A Aguilar, Miquel
%A Pastor, Pau
%A Planellas, Lluis
%A Cosgaya, Marina
%A Garcia Caldentey, Juan
%A Caballol, Nuria
%A Legarda, Ines
%A Hernandez Vara, Jorge
%A Cabo, Iria
%A Lopez Manzanares, Luis
%A Gonzalez Aramburu, Isabel
%A Avila Rivera, Maria A.
%A Catalan, Maria J.
%A Nogueira, Victor
%A Puente, Victor
%A Ruiz de Arcos, Maria
%A Borrue, Carmen
%A Solano Vila, Berta
%A Alvarez Sauco, Maria
%A Vela, Lydia
%A Escalante, Sonia
%A Cubo, Esther
%A Carrillo Padilla, Francisco
%A Martinez Castrillo, Juan C.
%A Sanchez Alonso, Pilar
%A Alonso Losada, Maria G.
%A Lopez Ariztegui, Nuria
%A Gaston, Itziar
%A Clavero, Pedro
%A Kulisevsky, Jaime
%A Blazquez Estrada, Marta
%A Seijo, Manuel
%A Ruiz Martinez, Javier
%A Valero, Caridad
%A Kurtis, Monica
%A de Fabregues, Oriol
%A Gonzalez Ardura, Jessica
%A Ordas, Carlos
%A Lopez Diaz, Luis M.
%A McAfee, Darrian
%A Martinez-Martin, Pablo
%A Mir, Pablo
%A COPPADIS Study Grp
%T Predictors of clinically significant quality of life impairment in Parkinson's disease
%D 2021
%U https://hdl.handle.net/10668/27942
%X Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p = 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p = 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
%K Nonmotor symptoms
%K Gender-differences
%K Impact
%K Disability
%K Questionnaire
%K Progression
%K Scale
%K Determinants
%K Validation
%K Onset
%~